3,4-Dichloromethylphenidate Stats & Data
3,4-ctmp
3,4-dcmp
Dichloromethylphenidate
34ctmp
Psychoactive Class
Stimulant
Receptor Profile
Receptor Actions
Agonists
5-HT2B receptor agonist
Inhibitors
Dopamine reuptake inhibitor
Norepinephrine reuptake inhibitor
Effect Profile
Curated + 5 Reports
Stimulant
6.4
Strong anxiety/jitters, euphoria, and focus with mild stimulation
Stimulation / Energy×3
5
Euphoria / Mood Lift×2
9
Focus / Productivity×2
9
Anxiety / Jitters×1
10
Based on reports from:
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Full tolerance
1d
Half tolerance
10d
Baseline
~18d
Experience Report Analysis
Erowid
5
Reports
2014–2019
Date Range
5
With Age Data
4
Effects Detected
Demographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 5 experience reports (5 Erowid)
5
Reports
4
Effects Detected
2
Positive
1
Adverse
1
Neutral
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 2
Focus Enhancement
80.0%
70%
Stimulation
80.0%
70%
Adverse Effects 1
Increased Heart Rate
100.0%
70%
Real-World Dose Distribution
62K DosesFrom 14 individual dose entries
Oral (n=7)
Median: 5.0mg
25th: 5.0mg
75th: 5.5mg
90th: 6.0mg
mg/kg median: 0.068
mg/kg 75th: 0.084
Insufflated (n=6)
Median: 6.5mg
25th: 6.0mg
75th: 7.0mg
90th: 9.5mg
mg/kg median: 0.096
mg/kg 75th: 0.102
Form / Preparation
Most common forms and preparations reported
References
Cited References
- Arunotayanun (2014) - 5-HT2B receptor activity
- Davidson et al. (2018) - Neurochemical assessment in rat nucleus accumbens
- Davies et al. (2004) - Synthesis and binding affinities
- Drugs-Forum: 3,4-CTMP Wiki
- Erowid: 3,4-Dichloromethylphenidate Experience Reports
- PsychonautWiki: 3,4-CTMP
- Rothman et al. (2000) - 5-HT2B receptors and cardiac valvulopathy
- Wikipedia: 3,4-Dichloromethylphenidate
- Davies et al. (2004) - Synthesis and binding affinities
- Davidson et al. (2018) - Neurochemical assessment in rat nucleus accumbens